256 related articles for article (PubMed ID: 31277094)
1. IMP3 is a biomarker for non-muscle-invasive urothelial carcinoma of the bladder associated with an aggressive phenotype.
Yang F; Zhou Q; Meng L; Xing N
Medicine (Baltimore); 2019 Jul; 98(27):e16009. PubMed ID: 31277094
[TBL] [Abstract][Full Text] [Related]
2. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder.
Sitnikova L; Mendese G; Liu Q; Woda BA; Lu D; Dresser K; Mohanty S; Rock KL; Jiang Z
Clin Cancer Res; 2008 Mar; 14(6):1701-6. PubMed ID: 18347170
[TBL] [Abstract][Full Text] [Related]
3. IMP3 expression in urothelial carcinomas of the urinary bladder.
Ozdemir NO; Türk NS; Düzcan E
Turk Patoloji Derg; 2011 Jan; 27(1):31-7. PubMed ID: 21469424
[TBL] [Abstract][Full Text] [Related]
4. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
[TBL] [Abstract][Full Text] [Related]
6. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
[TBL] [Abstract][Full Text] [Related]
7. High insulin-like growth factor mRNA-binding protein 3 (IMP3) protein expression is associated with poor survival in muscle-invasive bladder cancer.
Szarvas T; vom Dorp F; Niedworok C; Melchior-Becker A; Fischer JW; Singer BB; Reis H; Bánkfalvi Á; Schmid KW; Romics I; Ergün S; Rübben H
BJU Int; 2012 Sep; 110(6 Pt B):E308-17. PubMed ID: 22500655
[TBL] [Abstract][Full Text] [Related]
8. Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder.
Xylinas E; Cha EK; Khani F; Kluth LA; Rieken M; Volkmer BG; Hautmann R; Küfer R; Chen YT; Zerbib M; Rubin MA; Scherr DS; Shariat SF; Robinson BD
J Urol; 2014 Mar; 191(3):830-41. PubMed ID: 23994370
[TBL] [Abstract][Full Text] [Related]
9. Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1.
Rausch S; Hennenlotter J; Teepe K; Kuehs U; Aufderklamm S; Bier S; Mischinger J; Gakis G; Stenzl A; Schwentner C; Todenhöfer T
Urol Oncol; 2015 Oct; 33(10):426.e21-9. PubMed ID: 26231311
[TBL] [Abstract][Full Text] [Related]
10. Bladder Tumor Subtype Commitment Occurs in Carcinoma
Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
[TBL] [Abstract][Full Text] [Related]
11. DDR2 overexpression in urothelial carcinoma indicates an unfavorable prognosis: a large cohort study.
Tsai MC; Li WM; Huang CN; Ke HL; Li CC; Yeh HC; Chan TC; Liang PI; Yeh BW; Wu WJ; Lim SW; Li CF
Oncotarget; 2016 Nov; 7(48):78918-78931. PubMed ID: 27793038
[TBL] [Abstract][Full Text] [Related]
12. CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder.
Choi JW; Kim Y; Lee JH; Kim YS
Int J Urol; 2013 Feb; 20(2):251-5. PubMed ID: 22905972
[TBL] [Abstract][Full Text] [Related]
13. Sp1 is overexpressed and associated with progression and poor prognosis in bladder urothelial carcinoma patients.
Zhu J; Lu Z; Ke M; Cai X
Int Urol Nephrol; 2022 Jul; 54(7):1505-1512. PubMed ID: 35467245
[TBL] [Abstract][Full Text] [Related]
14. Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer.
Boman K; Segersten U; Ahlgren G; Eberhard J; Uhlén M; Jirström K; Malmström PU
BMC Urol; 2013 Apr; 13():17. PubMed ID: 23565664
[TBL] [Abstract][Full Text] [Related]
15. Identification of an immune-related long non-coding RNA signature and nomogram as prognostic target for muscle-invasive bladder cancer.
Song Y; Jin D; Chen J; Luo Z; Chen G; Yang Y; Liu X
Aging (Albany NY); 2020 Jun; 12(12):12051-12073. PubMed ID: 32579540
[TBL] [Abstract][Full Text] [Related]
16. Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer.
Patry G; Hovington H; Larue H; Harel F; Fradet Y; Lacombe L
Int J Cancer; 2008 Apr; 122(7):1592-7. PubMed ID: 18058798
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.
Jung M; Kim B; Moon KC
Histopathology; 2019 Feb; 74(3):483-493. PubMed ID: 30286252
[TBL] [Abstract][Full Text] [Related]
20. Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors.
Li L; Xu H; Spaulding BO; Cheng L; Simon R; Yao JL; di Sant'Agnese PA; Bourne PA; Huang J
Hum Pathol; 2008 Aug; 39(8):1205-11. PubMed ID: 18547613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]